Cardiovascular drugs and asthma

Cardiovascular Drugs and Asthma

Approximately 300 million people worldwide suffer from asthma. Asthma has become a global health concern. Despite the significant improvement in the diagnosis, treatment, and prognosis of asthma, there are still some issues that cannot be ignored. For example, as a globally high-risk chronic disease, hypertension with chronic obstructive pulmonary disease (COPD) is 7.4%, but when patients use this medicine, due to the lack of understanding of asthma by patients and doctors, it leads to many avoidable drug properties. asthma. Among cardiovascular drugs, drugs such as aspirin and angiotensin-converting enzyme inhibitor (ACEI) may cause or aggravate asthma.

Aspirin Aspirin Asthma (AIA) is not an allergic disease but a chronic inflammatory response. The main pathophysiological mechanism of aspirin asthma is the metabolic process affecting arachidonic acid in mast cells and eosinophils. Some scholars refer to aspirin-induced respiratory diseases collectively as aspirin aggravated respiratory diseases (AERD). Patients with AIA should discontinue aspirin. If airway inflammation persists, glucocorticoids are still the preferred treatment. Leukotriene regulators can As an aid. These patients should try to avoid using aspirin or other NSAIDs again. If you must use aspirin, consider aspirin desensitization therapy to make patients tolerate aspirin.

Angiotensin-converting enzyme inhibitor (ACEI) ACEI acts by competitively inhibiting angiotensin-converting enzyme (ACE). ACE is a non-specific enzyme that, in addition to converting angiotensin I (Ang I) to angiotensin II (Ang II), also catalyzes the degradation of peptide-like vasodilators such as bradykinin. Therefore, ACEI reduces the concentration of AngII, which can lead to the accumulation of bradykinin, which stimulates mast cells to secrete histamine, and can directly act on the β2 receptor on smooth muscle cells, causing contraction of smooth muscle. The main adverse reaction of ACEI is cough, and the incidence of cough is 5% to 10%. Cough caused by ACEI usually occurs from 1 week to several months after administration, varying degrees, and more common at night. Mainly manifested as dry cough, sometimes with itchy throat, pharyngeal foreign body sensation and cough bursts. It may be difficult to distinguish from some respiratory diseases, such as cough variant asthma.

Cardiovascular Diseases and Asthma As a globally high-risk chronic disease, clinicians recognize that the impact of common cardiovascular medications on asthma is particularly important in this era of medical expertise. Aspirin and ACEI drugs are commonly used in cardiovascular medicine and are also closely related to asthma. The incidence of AIA is relatively high. If you can correctly understand the characteristics of his medical history, you can avoid and effectively diagnose and treat AIA. In addition, beta blockers are an absolute contraindication to asthma, and clinicians should be alert to patients with undiagnosed asthma before taking the drug. Cough caused by ACEI is easily confused with cough variant asthma, and withdrawal can be alleviated. Medication should be noted on weekdays.

Cardiovascular Drugs and Asthma